Literature DB >> 11520076

Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells.

R Zennadi1, Z Abdel-Wahab, H F Seigler, T L Darrow.   

Abstract

Recognition of melanoma antigens by HLA class-II-restricted CD4(+) T lymphocytes has been investigated. Two cytotoxic CD4(+) T cell lines were established by stimulating PBLs from a melanoma patient with either parental or IFN-gamma-transduced autologous tumor cells. These T cells secreted IL-4, but not IL-2, IFN-gamma, or TNF-beta, in response to the autologous melanoma cells, suggesting that they belong to the Th2 subtype. Their cytotoxicity was directed against the IFN-gamma-transduced melanoma cells and was HLA-DR-restricted. The autologous and two allogeneic IFN-gamma-modified melanoma cell lines shared melanoma antigen(s) presented in the context of HLA-DR15. HLA-DR15(+) nonmelanoma cells were resistant targets indicating that the shared antigen(s) is melanoma associated. Parental autologous and HLA-DR-matched allogeneic melanoma cell lines, displaying low levels of HLA-DR antigens, induced Th2 proliferation and cytokine release, but were insensitive to lysis prior to upregulation of HLA-DR and Fas antigens by IFN-gamma. Cytolysis was inhibited by anti-HLA-DR and by anti-Fas antibodies, suggesting that the cytolysis is mediated via the Fas pathway. While small amounts of HLA-DR15 molecules on melanoma cells are sufficient for Th2 proliferation and cytokine release, higher amounts of HLA-DR15 and the expression of Fas are required for CD4(+)-mediated lysis. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520076     DOI: 10.1006/cimm.2001.1809

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  6 in total

1.  Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma.

Authors:  Paul F Robbins; Mona El-Gamil; Yong F Li; Gang Zeng; Mark Dudley; Steven A Rosenberg
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

2.  HLA class I and class II frequencies in patients with cutaneous malignant melanoma from southeastern Spain: the role of HLA-C in disease prognosis.

Authors:  José A Campillo; Jorge A Martínez-Escribano; Manuel Muro; Rosa Moya-Quiles; Luis A Marín; Olga Montes-Ares; Natalia Guerra; Paloma Sánchez-Pedreño; José F Frías; José A Lozano; Ana M García-Alonso; M Rocío Alvarez-López
Journal:  Immunogenetics       Date:  2005-12-20       Impact factor: 2.846

3.  Dendritic cells loaded with mRNA encoding full-length tumor antigens prime CD4+ and CD8+ T cells in melanoma patients.

Authors:  An M T Van Nuffel; Daphné Benteyn; Sofie Wilgenhof; Lauranne Pierret; Jurgen Corthals; Carlo Heirman; Pierre van der Bruggen; Pierre G Coulie; Bart Neyns; Kris Thielemans; Aude Bonehill
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

Review 4.  Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.

Authors:  Aurélie Durgeau; Yasemin Virk; Stéphanie Corgnac; Fathia Mami-Chouaib
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

5.  HLA-DRB116:01 and HLA-DQB105:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma.

Authors:  Xu Wang; Francisco Almazan; Yoel Genaro Montoyo-Pujol; Antonia Martin-Casares; Aurelio Martin; Teresa Cabrera; Miguel Angel López-Nevot
Journal:  J Oncol       Date:  2021-09-30       Impact factor: 4.375

6.  On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases.

Authors:  M R Bernsen; L Håkansson; B Gustafsson; L Krysander; B Rettrup; D Ruiter; A Håkansson
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.